Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.

Glutsch V, Grän F, Weber J, Gesierich A, Goebeler M, Schilling B.

J Immunother Cancer. 2019 Jul 12;7(1):181. doi: 10.1186/s40425-019-0655-4.

2.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
3.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

4.

Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.

Grän F, Goebeler M, Gesierich A.

Eur J Dermatol. 2019 Feb 1;29(1):107-108. doi: 10.1684/ejd.2019.3511. No abstract available.

PMID:
30998207
5.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

6.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8.

7.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
8.

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry.

Gassenmaier M, Keim U, Leiter U, Eigentler TK, Röcken M, Gesierich A, Moritz RKC, Heinzerling L, Tüting T, Wollina U, Garbe C.

J Am Acad Dermatol. 2019 May;80(5):1299-1307.e7. doi: 10.1016/j.jaad.2019.01.044. Epub 2019 Jan 29.

PMID:
30703453
9.

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.

Appenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald A, Schartl M, Goebeler M, Meierjohann S.

Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18.

PMID:
30561760
10.

Nocardiosis in a patient with anti-PD-1-associated colitis treated with infliximab.

Glutsch V, Gesierich A, Goebeler M, Forster J, Schilling B.

Eur J Cancer. 2018 Sep;101:284-286. doi: 10.1016/j.ejca.2018.06.014. Epub 2018 Jul 13. No abstract available.

PMID:
30017385
11.

Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.

Milsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M, Schadendorf D, Schilling B.

Eur J Cancer. 2018 Aug;99:58-65. doi: 10.1016/j.ejca.2018.05.012. Epub 2018 Jun 12.

PMID:
29906735
12.

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.

Thiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A.

Melanoma Res. 2018 Oct;28(5):465-468. doi: 10.1097/CMR.0000000000000458.

PMID:
29781871
13.

Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.

Haug V, Behle V, Benoit S, Kneitz H, Schilling B, Goebeler M, Gesierich A.

Br J Dermatol. 2018 Oct;179(4):993-994. doi: 10.1111/bjd.16780. Epub 2018 Jul 23. No abstract available.

PMID:
29758087
14.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG).

Cancer Immunol Immunother. 2018 May;67(5):825-834. doi: 10.1007/s00262-018-2134-z. Epub 2018 Feb 27.

PMID:
29487980
15.

[Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care].

Glossmann JP, Skoetz N, Starbatty B, Bischoff M, Leyvraz S, Westekemper H; AG SOP; Unter-AG Konjunktivales Melanom, Heindl LM.

Ophthalmologe. 2018 Jun;115(6):489-498. doi: 10.1007/s00347-018-0664-6. German.

PMID:
29468295
16.

[Slate-gray macules in the axillae].

Schmid C, Reichel A, Kerstan A, Gesierich A, Hamm H.

Hautarzt. 2018 Feb;69(2):177-179. doi: 10.1007/s00105-017-4098-x. German. No abstract available.

PMID:
29264631
17.

Impact of extended lymphadenectomy on morbidity and regional recurrence-free survival in melanoma patients.

Baur J, Mathe K, Gesierich A, Weyandt G, Wiegering A, Germer CT, Pelz JOW.

J Dermatolog Treat. 2018 Aug;29(5):515-521. doi: 10.1080/09546634.2017.1398395. Epub 2017 Nov 16.

PMID:
29098910
18.

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.

Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C.

BMC Cancer. 2017 Aug 10;17(1):536. doi: 10.1186/s12885-017-3529-5.

19.

Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.

Müller-Richter UDA, Gesierich A, Kübler AC, Hartmann S, Brands RC.

Ann Surg Oncol. 2017 Oct;24(11):3430-3437. doi: 10.1245/s10434-017-5993-1. Epub 2017 Jul 31. Review.

20.

Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.

Thiem A, Kneitz H, Schummer P, Herz S, Schrama D, Houben R, Goebeler M, Schilling B, Gesierich A.

Acta Derm Venereol. 2017 Nov 15;97(10):1252-1254. doi: 10.2340/00015555-2757. No abstract available.

Supplemental Content

Loading ...
Support Center